• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

Recent Advances in the Study of [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride (CAS: 1261231-77-9)

In recent years, [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride (CAS: 1261231-77-9) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique pyrimidine and piperidine structural motifs, has been the subject of numerous studies aimed at exploring its potential applications in drug discovery and development. The following research brief synthesizes the latest findings related to this compound, highlighting its chemical properties, biological activities, and therapeutic potential.

Recent studies have focused on the synthesis and optimization of [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride, with particular attention to its role as a key intermediate in the development of kinase inhibitors. Kinases are critical targets in the treatment of various diseases, including cancer, inflammatory disorders, and neurodegenerative conditions. Researchers have reported successful modifications of the compound's core structure to enhance its binding affinity and selectivity for specific kinase targets, thereby improving its therapeutic efficacy.

One of the most notable advancements in this area is the compound's application in the design of selective JAK2 inhibitors. JAK2, a member of the Janus kinase family, plays a pivotal role in cytokine signaling pathways and is implicated in myeloproliferative neoplasms. Preclinical studies have demonstrated that derivatives of [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride exhibit potent inhibitory activity against JAK2, with promising results in reducing tumor growth and improving survival rates in animal models. These findings underscore the compound's potential as a lead candidate for the development of novel anticancer therapies.

In addition to its kinase inhibitory properties, [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride has also been investigated for its role in modulating other biological pathways. Recent research has explored its interactions with G-protein coupled receptors (GPCRs), which are involved in a wide range of physiological processes. Preliminary data suggest that the compound may serve as a scaffold for the development of GPCR-targeted drugs, offering new avenues for the treatment of cardiovascular and metabolic disorders.

From a chemical perspective, the stability and solubility of [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride have been subjects of optimization efforts. Researchers have employed various formulation strategies, including salt formation and prodrug approaches, to enhance the compound's pharmacokinetic properties. These modifications have resulted in improved bioavailability and reduced toxicity, further supporting its potential for clinical translation.

In conclusion, the ongoing research on [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methyl-amine hydrochloride (CAS: 1261231-77-9) highlights its versatility and promise as a valuable tool in drug discovery. Its applications in kinase inhibition and GPCR modulation, coupled with advancements in chemical optimization, position this compound as a key player in the development of next-generation therapeutics. Future studies are expected to delve deeper into its mechanistic insights and clinical potential, paving the way for innovative treatments across a spectrum of diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)